Literature DB >> 18510481

Comparison of different LDL apheresis methods.

Ulrich Julius1, Antje Frind, Sergej Tselmin, Steffi Kopprasch, Ines Poberschin, Gabriele Siegert.   

Abstract

This article presents the generally accepted indications for LDL apheresis treatment. The available LDL apheresis methods differ with respect to acute relative reductions of LDL cholesterol; mean values after the LDL apheresis treatments are not different. Serum triglycerides, HDL-cholesterol, and lipoprotein(a) are also acutely reduced. Available LDL apheresis methods differ with respect to their impact on the coagulation system, on C-reactive protein and on leukocyte count. Cardiovascular events are clearly reduced by the LDL apheresis methods. There is an urgent need to prospectively compare the different LDL apheresis methods taking into account hard end points. The lower target values for LDL cholesterol suggested by international guidelines for high-risk patients will certainly require a more widespread use of LDL apheresis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18510481     DOI: 10.1586/14779072.6.5.629

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  3 in total

1.  LDL apheresis as an alternate method for plasma LPS purification in healthy volunteers and dyslipidemic and septic patients.

Authors:  Auguste Dargent; Jean-Paul Pais de Barros; Samir Saheb; Randa Bittar; Wilfried Le Goff; Alain Carrié; Thomas Gautier; Isabelle Fournel; Anne Laure Rerole; Hélène Choubley; David Masson; Laurent Lagrost; Jean-Pierre Quenot
Journal:  J Lipid Res       Date:  2020-10-09       Impact factor: 5.922

Review 2.  Optimal management of familial hypercholesterolemia: treatment and management strategies.

Authors:  Mohammad Hassan Nemati; Behrooz Astaneh
Journal:  Vasc Health Risk Manag       Date:  2010-12-03

3.  Lipid apheresis: oxidative stress, rheology, and vasodilatation.

Authors:  K-P Mellwig; E Pulawski; D Horstkotte; F van Buuren
Journal:  Clin Res Cardiol Suppl       Date:  2012-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.